Verteporfin-loaded supramolecular micelles for enhanced cisplatin-based chemotherapy via autophagy inhibition

2022 ◽  
Author(s):  
Junwei Ye ◽  
Bo Yu ◽  
Haitao Hu ◽  
Dongfang Zhou ◽  
Qiao Jin ◽  
...  
Keyword(s):  
Cancer Therapy ◽  
Therapeutic Efficacy ◽  
Chemotherapeutic Agents ◽  
Autophagy Inhibitor ◽  
Autophagy Inhibition

Cisplatin (CDDP) is one of the most successful chemotherapeutic agents for cancer therapy. However, CDDP can activate pro-survival autophagy which inhibits therapeutic efficacy of CDDP. Herein, autophagy inhibitor verteporfin (VTPF)...

KIDNEY INJURY IN CANCER THERAPY

2018 ◽  
Vol 22 (5) ◽  
pp. 17-24 ◽  
Author(s):  
E. V. Burnasheva ◽  
Y. V. Shatokhin ◽  
I. V. Snezhko ◽  
A. A. Matsuga
Keyword(s):  
Risk Factors ◽  
Acute Kidney Injury ◽  
Cancer Therapy ◽  
Cancer Patients ◽  
Cytotoxic Effect ◽  
Tumor Lysis Syndrome ◽  
Kidney Injury ◽  
Chemotherapeutic Agents ◽  
Oxygen Intermediates ◽  
Circulating Blood Volume

Кidney injury is a frequent and significant complication of cancer and cancer therapy. The kidneys are susceptible to injury from malignant infiltration, damage by metabolites of malignant cells, glomerular  injury, nephrotoxic drugs including chemotherapeutic agents. Also  bone marrow transplantation complications, infections with immune  suppression (including septicemia), tumor lysis syndrome should be  taken into account. Chemotherapeutic agents are a common cause  of acute kidney injury but can potentially lead to chronic kidney  disease development in cancer patients. This article summarizes risk  factors of acute kidney injury in cancer patients. Risk factors are  divided into two groups. The systemic are decrease of total  circulating blood volume, infiltration of kidney tissue by tumor cells,  dysproteinemia, electrolyte disturbances. The local (renal) risk  factors are microcirculation disturbances, drugs biotransformation  with formation of reactive oxygen intermediates, high concentration of nephrotoxic agents in proximal tubules and its  sensitivity to ischemia. Drug-related risk factors include: drugs  combination with cytotoxic effect high doses long term use necessity, direct cytotoxic effect of not only chemotherapeutic agents but also its metabolites, mean solubility forming intratubular  precipitates. Early diagnosis, timely prevention and treatment of  these complications provide significantly improve nononcologic results of treatment.

Hybrid Compounds & Oxidative Stress Induced Apoptosis in Cancer Therapy

2020 ◽  
Vol 27 (13) ◽  
pp. 2118-2132 ◽  
Author(s):  
Aysegul Hanikoglu ◽  
Hakan Ozben ◽  
Ferhat Hanikoglu ◽  
Tomris Ozben
Keyword(s):  
Oxidative Stress ◽  
Drug Resistance ◽  
Side Effects ◽  
Cancer Therapy ◽  
Tumor Cells ◽  
Anticancer Drugs ◽  
Chemotherapeutic Agents ◽  
Oxidation Reactions ◽  
Hybrid Compounds ◽  
Induced Apoptosis

: Elevated Reactive Oxygen Species (ROS) generated by the conventional cancer therapies and the endogenous production of ROS have been observed in various types of cancers. In contrast to the harmful effects of oxidative stress in different pathologies other than cancer, ROS can speed anti-tumorigenic signaling and cause apoptosis of tumor cells via oxidative stress as demonstrated in several studies. The primary actions of antioxidants in cells are to provide a redox balance between reduction-oxidation reactions. Antioxidants in tumor cells can scavenge excess ROS, causing resistance to ROS induced apoptosis. Various chemotherapeutic drugs, in their clinical use, have evoked drug resistance and serious side effects. Consequently, drugs having single-targets are not able to provide an effective cancer therapy. Recently, developed hybrid anticancer drugs promise great therapeutic advantages due to their capacity to overcome the limitations encountered with conventional chemotherapeutic agents. Hybrid compounds have advantages in comparison to the single cancer drugs which have usually low solubility, adverse side effects, and drug resistance. This review addresses two important treatments strategies in cancer therapy: oxidative stress induced apoptosis and hybrid anticancer drugs.

Recent advances in the development of metal-organic framework-based gas nanoplatforms for synergistic cancer therapy

2021 ◽  
Author(s):  
Yong Yao ◽  
Danni Jing ◽  
Jianan Zhang ◽  
Youyou Huang ◽  
Xiru Qin ◽  
...  
Keyword(s):  
Cancer Therapy ◽  
Therapeutic Efficacy ◽  
Metal Organic Framework ◽  
Research Field ◽  
Tumor Site ◽  
Recent Advances ◽  
Metal Organic ◽  
Organic Framework

Featuring high therapeutic efficacy, biocompatibility, and biosafety, gas therapy as a burgeoning and promising research field has attracted considerable attention in biomedicine. However, the lack of the tumor site accumulation...

Tandem Molecular Self-assembly for Selective Lung Cancer Therapy with Two Orders of Magnitude Increase in Efficiency

Nanoscale ◽  
2021 ◽  
Author(s):  
Debin Zheng ◽  
Jingfei Liu ◽  
Yinghao Ding ◽  
Limin Xie ◽  
Yingying Zhang ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cancer Therapy ◽  
Anticancer Drugs ◽  
Self Assembly ◽  
Therapeutic Efficacy ◽  
Self Assembling ◽  
Lung Cancer Therapy ◽  
Magnitude Increase

In situ self-assembling of prodrug molecules into nanomedicine can elevate the therapeutic efficacy of anticancer medications by enhancing the targeting and enrichment of anticancer drugs at tumor sites. However, the...

scholarly journals Assessment of therapeutic efficacy and fate of engineered human mesenchymal stem cells for cancer therapy

2009 ◽  
Vol 106 (12) ◽  
pp. 4822-4827 ◽  
Author(s):  
L. S. Sasportas ◽  
R. Kasmieh ◽  
H. Wakimoto ◽  
S. Hingtgen ◽  
J. A. J. M. van de Water ◽  
...  
Keyword(s):  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Cancer Therapy ◽  
Therapeutic Efficacy ◽  
Human Mesenchymal Stem Cells

Autophagy Inhibition as a Strategy for Cancer Therapy

2016 ◽  
pp. 279-314 ◽  
Author(s):  
Xiaohong Ma ◽  
Shengfu Piao ◽  
Quentin McAfee ◽  
Ravi K. Amaravadi
Keyword(s):  
Cancer Therapy ◽  
Autophagy Inhibition

A Unique Self-Reporting Photosensitizer Enabling Simultaneous Photodynamic Therapy and Real-Time Monitoring Phototheranostic Process in a Dynamic Dual-Color Mode

2021 ◽  
Author(s):  
Dong-Hui Wang ◽  
Li-Jian Chen ◽  
Xu Zhao ◽  
Xiu-Ping Yan
Keyword(s):  
Photodynamic Therapy ◽  
Cancer Therapy ◽  
Real Time ◽  
Small Molecule ◽  
Therapeutic Efficacy ◽  
Real Time Monitoring ◽  
Dual Color

Phototheranostics has attracted great interest in cancer therapy. Small-molecule self-reporting photosensitizers, one kind of idea agents in phototheranostics, enable simultaneous photodynamic therapy (PDT) and feedback of therapeutic efficacy. However, previous...

scholarly journals A glutathione responsive pyrrolopyrrolidone nanotheranostic agent for turn-on fluorescence imaging guided photothermal/photodynamic cancer therapy

2019 ◽  
Vol 3 (10) ◽  
pp. 2143-2150 ◽  
Author(s):  
Jianhua Zou ◽  
Lei Xue ◽  
Nan Yang ◽  
Yanfang Ren ◽  
Zhe Fan ◽  
...  
Keyword(s):  
Cancer Therapy ◽  
Fluorescence Imaging ◽  
Therapeutic Efficacy ◽  
Turn On ◽  
Photodynamic Cancer Therapy

Herein, GSH responsive pyrrolopyrrolidone derivatives with enhanced photodynamic/photothermal therapeutic efficacy were designed, which can be used as colorimetric probes.

scholarly journals Pharmacophore hybridisation and nanoscale assembly to discover self-delivering lysosomotropic new-chemical entities for cancer therapy

2020 ◽  
Vol 11 (1) ◽  
Author(s):  
Zhao Ma ◽  
Jin Li ◽  
Kai Lin ◽  
Mythili Ramachandran ◽  
Dalin Zhang ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Cancer Therapy ◽  
Self Assembly ◽  
The Self ◽  
Single Drug ◽  
Drug Nanoparticles ◽  
Lysosomal Dysfunction ◽  
New Chemical Entities ◽  
Autophagy Inhibition

Abstract Integration of the unique advantages of the fields of drug discovery and drug delivery is invaluable for the advancement of drug development. Here we propose a self-delivering one-component new-chemical-entity nanomedicine (ONN) strategy to improve cancer therapy through incorporation of the self-assembly principle into drug design. A lysosomotropic detergent (MSDH) and an autophagy inhibitor (Lys05) are hybridised to develop bisaminoquinoline derivatives that can intrinsically form nanoassemblies. The selected BAQ12 and BAQ13 ONNs are highly effective in inducing lysosomal disruption, lysosomal dysfunction and autophagy blockade and exhibit 30-fold higher antiproliferative activity than hydroxychloroquine used in clinical trials. These single-drug nanoparticles demonstrate excellent pharmacokinetic and toxicological profiles and dramatic antitumour efficacy in vivo. In addition, they are able to encapsulate and deliver additional drugs to tumour sites and are thus promising agents for autophagy inhibition-based combination therapy. Given their transdisciplinary advantages, these BAQ ONNs have enormous potential to improve cancer therapy.

Sign in / Sign up

Export Citation Format

Share Document